Global Ultomiris Drug Market Size & Outlook, 2025-2030
Global ultomiris drug market, 2019-2030 (US$M)
Related Markets
Global ultomiris drug market highlights
- The global ultomiris drug market generated a revenue of USD 3,924.0 million in 2024 and is expected to reach USD 18,039.0 million by 2030.
- The market is expected to grow at a CAGR (2025 - 2030) of 28.5% by 2030.
- In terms of segment, paroxysmal nocturnal hemoglobinuria (pnh) accounted for a revenue of USD 5,155.2 million in 2024.
- Paroxysmal Nocturnal Hemoglobinuria (PNH) is the most lucrative indication segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
Global data book summary
| Market revenue in 2024 | USD 3,924.0 million |
| Market revenue in 2030 | USD 18,039.0 million |
| Growth rate | 28.5% (CAGR from 2025 to 2030) |
| Largest segment | Paroxysmal nocturnal hemoglobinuria (pnh) |
| Fastest growing segment | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Historical data covered | 2019 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Other key industry trends
- In terms of revenue, the North America accounted for 45.0% of the global ultomiris drug market in 2024.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ultomiris Drug Market Scope
Ultomiris Drug Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
Global ultomiris drug market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ultomiris drug market will help companies and investors design strategic landscapes.
Paroxysmal nocturnal hemoglobinuria (pnh) was the largest segment with a revenue share of 131.38% in 2024. Horizon Databook has segmented the Global ultomiris drug market based on paroxysmal nocturnal hemoglobinuria (pnh) covering the revenue growth of each sub-segment from 2019 to 2030.
- Global Ultomiris Drug Indication Outlook (Revenue, USD Million, 2019-2030)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Generalized Myasthenia Gravis (gMG)
- Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Global Ultomiris Drug End Use Outlook (Revenue, USD Million, 2019-2030)
- Adult
- Pediatric
- Global Ultomiris Drug Distribution Channel Outlook (Revenue, USD Million, 2019-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to Global ultomiris drug market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global ultomiris drug market databook
-
Our clientele includes a mix of ultomiris drug market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global ultomiris drug market , including forecasts for subscribers. This global databook contains high-level insights into Global ultomiris drug market from 2019 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global ultomiris drug market size, by regions, 2019-2030 (US$M)
Top 10 countries: Ultomiris drug market size, 2024 (US$M)
Global ultomiris drug market share, by indication, 2024 & 2030 (%, US$M)
Ultomiris drug market: Opportunity assessment by country
Global ultomiris drug market, by region, 2024 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
